Lilly Settles On Rolling Submission For Tirzepatide In Obesity

 
• By Joseph Haas

Plan for rolling submission means US FDA filing of GIP/GLP1 agonist in obesity could be complete by April 2023, setting up possibility of late 2023 approval.

Accelerated process
Lilly hopes the rolling submission process will acclerate tirzepatide's path to the weight-loss market • Source: Shutterstock

More from Strategy

More from Business